Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): A randomised, double-blind, placebo-controlled phase 2 trial

The Lancet

Volumn 386, Issue 9992, 2015, Pages 452-460

  Hovingh, G Kees ^a   Kastelein, John J P ^a,b   Van Deventer, Sander J H ^b,c   Round, Patrick ^b   Ford, John ^b,d   Saleheen, Danish ^e   Rader, Daniel J ^e   Brewer, H Bryan ^f   Barter, Philip J ^g  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b Dezima Pharma BV   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d Xention   (United Kingdom)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f MEDSTAR RESEARCH INSTITUTE   (United States)

^g UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; ROSUVASTATIN; TA 8995; UNCLASSIFIED DRUG; CHOLESTEROL ESTER TRANSFER PROTEIN; FLUOROBENZENE; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; QUINOLINE DERIVATIVE; SULFONAMIDE; TA-8995;

ADULT; AGED; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DYSLIPIDEMIA; FEMALE; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; MUSCLE DISEASE; OUTCOME ASSESSMENT; PARALLEL DESIGN; PATIENT SAFETY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; ADOLESCENT; ANTAGONISTS AND INHIBITORS; BLOOD; CLINICAL TRIAL; DENMARK; DRUG EFFECTS; DYSLIPIDEMIAS; MIDDLE AGED; NETHERLANDS; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DENMARK; DOUBLE-BLIND METHOD; DYSLIPIDEMIAS; FEMALE; FLUOROBENZENES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; NETHERLANDS; PYRIMIDINES; PYRROLES; QUINOLINES; SULFONAMIDES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84938748425     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(15)60158-1     Document Type: Article

References (19)

1. Cholesterol Treatment Trialists' (CTT) Collaboration C Baigent, L Blackwell, J Emberson et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials Lancet 376 2010 1670 1681
2. PJ Barter, KA Rye Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk J Lipid Res 53 2012 1755 1766
3. PJ Barter, M Caulfield, M Eriksson the ILLUMINATE Investigators Effects of torcetrapib in patients at high risk for coronary events N Engl J Med 357 2007 2109 2122
4. GG Schwartz, AG Olsson, M Abt the dal-OUTCOMES Investigators Effects of dalcetrapib in patients with a recent acute coronary syndrome N Engl J Med 367 2012 2089 2099
5. J Ford, M Lawson, D Fowler et al. Tolerability, pharmacokinetics and pharmacodynamics of TA-8995, a selective cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects Br J Clin Pharmacol 78 2014 498 508
6. AV Khera, M Cuchel, M de la Llera-Moya et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis N Engl J Med 364 2011 127 135
7. M de la Llera-Moya, D Drazul-Schrader, BF Asztalos, M Cuchel, DJ Rader, GH Rothblat The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages Arterioscler Thromb Vasc Biol 30 2010 796 801
8. TH Johannsen, R Frikke-Schmidt, J Schou, BG Nordestgaard, A Tybjærg-Hansen Genetic inhibition of CETP, ischemic vascular disease and mortality, and possible adverse effects J Am Coll Cardiol 60 2012 2041 2048
9. BF Voight, GM Peloso, M Orho-Melander et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study Lancet 380 2012 572 580
10. X Hu, JD Dietz, C Xia et al. Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition Endocrinology 150 2009 2211 2219
11. B Simic, M Hermann, SG Shaw et al. Torcetrapib impairs endothelial function in hypertension Eur Heart J 33 2012 1615 1624
12. SM Boekholdt, BJ Arsenault, S Mora et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis JAMA 307 2012 1302 1309
13. IMPROVE-IT Examining outcomes in subjects with acute coronary syndrome: vytorin (ezetimibe/simvastatin) vs simvastatin (P04103) https://clincialtrials.gov/ct2/show/NCT00202878 (accessed Dec 11, 2014).
14. BG Nordestgaard, MJ Chapman, K Ray the European Atherosclerosis Society Consensus Panel Lipoprotein(a) as a cardiovascular risk factor: current status Eur Heart J 31 2010 2844 2853
15. DJ Rader, GK Hovingh HDL and cardiovascular disease Lancet 384 2014 618 625
16. KK Ray, M Ditmarsch, D Kallend the dal-ACUTE Investigators The effect of cholesteryl ester transfer protein inhibition on lipids, lipoproteins, and markers of HDL function after an acute coronary syndrome: the dal-ACUTE randomized trial Eur Heart J 35 2014 1792 1800
17. American Heart Association Scientific Session Meeting, Nov 15-19 2014, Chicago, USA, poster# 2062 presented Nov 18, 2014 https://aha.apprisor.org/epsAbstractAHA.cfm?id=1 (accessed Dec 11, 2014).
18. A Rohatgi, A Khera, JD Berry et al. HDL Cholesterol Efflux Capacity and Incident Cardiovascular Events N Engl J Med 371 2014 2383 2393
19. AM Gotto Jr, U Kher, MS Chatterjee the DEFINE Investigators Lipids, safety parameters, and drug concentrations after an additional 2 years of treatment with anacetrapib in the DEFINE study J Cardiovasc Pharmacol Ther 19 2014 543 549